Johnson & Johnson Sees Surge in Sales Amid Pharmaceutical and Medical Tech Growth

Johnson & Johnson (NYSE:JNJ) is a multinational healthcare company operating across pharmaceuticals and medical technology.

The company's Innovative Medicine business addresses a range of diseases and medical conditions, including immunology, oncology, and neuroscience.

TREMFYA received an expanded approval for active psoriatic arthritis, while CAPLYTA was approved for prevention of relapse in schizophrenia.

MedTech operations span surgery, orthopaedics, cardiovascular care, vision, and other medical applications.

The company reported sales of approximately twenty-five billion dollars in the latest quarter, representing an increase from the corresponding period of the prior year.